|
09 Jan 2020 |
OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
|
|
08 Jan 2020 |
PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
|
|
08 Jan 2020 |
Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones
|
|
08 Jan 2020 |
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma
|
|
07 Jan 2020 |
Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
|
|
07 Jan 2020 |
AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain
|
|
07 Jan 2020 |
InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab
|
|
07 Jan 2020 |
Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis
|
|
07 Jan 2020 |
Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME
|
|
06 Jan 2020 |
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
|
|
06 Jan 2020 |
ESCAPE Bio Announces Excellent Safety and Tolerability in Phase 1 Study of Oral S1P5 Receptor Agonist ESB1609
|
|
06 Jan 2020 |
Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency
|
|
06 Jan 2020 |
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
|
|
03 Jan 2020 |
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
|
|
02 Jan 2020 |
Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)
|
|
02 Jan 2020 |
RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
|
|
02 Jan 2020 |
Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
|
|
02 Jan 2020 |
DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
|
|
01 Jan 2020 |
Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
|
|
01 Jan 2020 |
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)
|
|
30 Dec 2019 |
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
|
|
30 Dec 2019 |
BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
|
|
30 Dec 2019 |
Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris
|
|
30 Dec 2019 |
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
|
|
30 Dec 2019 |
Commencement of phase 1 trial for AZD0466 utilising DEP
|
